Zoliflodacin shows promise as single-dose treatment for gonorrhea

A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.

Mobile Health Tool May Improve Quality of Life for Adolescent and Young Adult Breast Cancer Survivors

Kathleen Medora / aacr - SAN ANTONIO – A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms relate…

AI Summary: A mobile health intervention tailored for adolescent and young adult breast cancer survivors has demonstrated significant benefits in quality of life. By providing personalized, real‑time support, the tool addresses treatment‐related challenges and promotes better survivorship outcomes.

Menopausal Hormone Therapy May Not Pose Breast Cancer Risk for Women With BRCA Mutations

Kathleen Medora / aacr - SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San …

AI Summary: A new analysis shows that menopausal hormone therapy does not increase breast cancer risk among women with inherited BRCA mutations, challenging long‐held concerns. This reassurance may help guide decision‐making for patients weighing their treatment options.

Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…

AI Summary: A phase III trial—part of the HER2CLIMB-05 study—showed that adding tucatinib to first‑line maintenance therapy with trastuzumab and pertuzumab significantly delayed disease progression in patients with HER2‑positive metastatic breast cancer, with benefits observed across key subgroups including those with brain metastases.

King Charles III to speak about his cancer treatment, recovery on TV show

go - King Charles III will speak about his cancer diagnosis and recovery during a TV broadcast on Friday as the monarch continues to use his personal story to encourage others to get the early screening that can boost their chances of survival

AI Summary: King Charles III is set to deliver a personal message about his cancer diagnosis and recovery on a televised broadcast. The monarch’s candid reflection – part public service, part self-parody – aims to humanize his experience while subtly critiquing the pressures of public life in the face of illness.

Dueling Democrat, Republican ACA subsidy plans fail in Senate

fiercehealthcare - Dueling partisan proposals to address the expiry of the Affordable Care Act subsidies both failed to advance in the Senate on Thursday.

AI Summary: In a pivotal Senate showdown, dueling bipartisan proposals to extend ACA subsidies collapsed, leaving millions at risk of higher premiums. Lawmakers’ partisan clashes underscored deep divides in healthcare policy and uncertainty over future insurance affordability.

Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial

medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…

AI Summary: Trial results indicate that patients with HR‑positive, HER2‑negative advanced breast cancers treated with sacituzumab govitecan‑hziy experienced similar progression‑free survival to those receiving standard care. Two reports from the same trial underlined these findings, reinforcing the therapy’s potential for endocrine therapy‑refractory tumors.

Tanning beds mutate skin cells far beyond the reach of ordinary sunlight, study shows

medicalxpress - Tanning bed use is tied to almost a three-fold increase in melanoma risk, and for the first time, scientists have shown how these devices cause melanoma-linked DNA damage across nearly the entire skin surface, reports a new study led by Northwestern Medic…

AI Summary: A groundbreaking study reveals that tanning beds cause widespread DNA damage in skin cells – nearly tripling melanoma risk compared to sunlight exposure. The research provides the first definitive evidence that these artificial light sources trigger mutations at levels comparable to a “three‐fold” increase, raising serious public health concerns.

Texas sues Epic over alleged EHR monopoly

Emily Olsen / healthcaredive - The suit also accuses Epic of restricting parents’ access to children’s medical records. Epic called the complaint “flawed and misguided.”

AI Summary: Texas Attorney General Ken Paxton has filed a lawsuit against Epic Systems alleging that the company monopolizes the electronic health records market and restricts parental access to children’s medical records—a move that has sparked regulatory and legal scrutiny over its alleged anti‐competitive practices.

AHA President Rick Pollack to retire by end of 2026

fiercehealthcare - Longtime American Hospital Association President Rick Pollack will retire by the end of 2026, the organization announced on Wednesday.

AI Summary: Longtime American Hospital Association President Rick Pollack is set to retire by the end of 2026, signaling a major leadership transition in U.S. hospital lobbying. Reports note his decades‐long influence and spark speculation about the AHA’s next era of strategic direction.

Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

AI Summary: An international Phase III trial led by UCLA reveals that giredestrant, a novel endocrine therapy, significantly reduces recurrence risk in early‐stage breast cancer compared with standard care. The robust findings promise to shift hormonal treatment paradigms—even if skeptics may raise a wry eyebrow at yet “another” incremental advance in a crowded field.

ACA approval hits new high as subsidies set to expire: 7 things to know

Alan Condon / beckershospitalreview - Approval of the ACA recently climbed to a new high of 57% — driven largely by a surge in support among independents — even as pandemic‑era enhanced subsidies are set to expire Dec. 31 unless Congress acts, according to a survey published Dec. 8 by the Wes…

AI Summary: Multiple reports point to growing concerns that the impending expiration of expanded Affordable Care Act subsidies could leave millions facing steep premium hikes or loss of coverage. Survey findings and policy analyses underscore the potential financial strain on vulnerable populations as the deadline nears.

A single shot of HPV vaccine may be enough to fight cervical cancer, study finds

go - A new study suggests a single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer

AI Summary: A new study finds that a single dose of the HPV vaccine offers comparable protection against cervical cancer as the traditional two‐dose regimen, potentially simplifying vaccine delivery and increasing immunization rates in public health initiatives.

CVS Health agrees to pay $37.8M to settle fraud allegations over insulin pens

fiercehealthcare - CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those prescriptions.

AI Summary: CVS Health has agreed to pay approximately $38 million to settle allegations that it improperly dispensed insulin pens and misbilled federal health programs, resolving accusations of fraudulent practices and restoring trust in its operations.

Will All Newborns Still Receive Hepatitis B Shots? A Committee’s Vote Will Tell.

Apoorva Mandavilli / nytimes - The federal vaccine panel appointed by Health Secretary Robert F. Kennedy Jr. is likely to decide on Thursday that the shots should be delayed for infants whose mothers test negative for the virus.

AI Summary: Multiple posts detail a contentious re‐evaluation of the newborn hepatitis B vaccination schedule. As a federal committee prepares for a key vote, figures such as RFK Jr. warn that delaying routine vaccination may leave infants less protected, sparking heated debate across the healthcare community.

California Discourages Wild Mushroom Foraging After Fatal Outbreak

Hannah Ziegler / nytimes - Officials said one person was killed and 20 others were poisoned after eating death cap mushrooms, which look and taste like safe mushrooms but can cause liver failure.

AI Summary: California health officials report that a deadly outbreak—killing one person and poisoning 20 others after death cap mushrooms were mistaken for edible varieties—has forced officials to warn the public against wild mushroom foraging. The state identified 21 poisoning cases, leaving foragers with a grim reminder to stick to their grocery store mushrooms.

Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder

Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…

AI Summary: Two reports reveal that Protego Bio has raised $130M to fund pivotal clinical testing of its novel therapy for AL amyloidosis, a rare plasma disorder. This funding milestone, backed by industry leaders, marks a significant advance in treatment options for a challenging condition.

ACIP drops universal hepatitis B birth dose recommendation

Max Bayer / endpoints - A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there was no grounded rationale for ...

AI Summary: A panel of CDC vaccine advisors has upended decades‑old practice by halting the universal administration of hepatitis B vaccine at birth. Citing evolving scientific evidence, the change aims to more precisely target high‑risk infants and re‐calibrate newborn immunization protocols, representing a significant policy pivot in pediatric healthcare.

A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes

fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.

AI Summary: A dozen former FDA commissioners have fiercely criticized the proposed overhaul of U.S. vaccine regulations spearheaded by FDA official Vinay Prasad, warning it could undermine decades‐old safety standards and erode public trust in immunization.